Cargando…
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Antibodies specific for TNFRSF receptors that bind soluble ligands without getting properly activated generally act as strong agonists upon FcγR binding. Systematic analyses revealed that the FcγR dependency of such antibodies to act as potent agonists is largely independent from isotype, FcγR type,...
Autores principales: | Medler, Juliane, Nelke, Johannes, Weisenberger, Daniela, Steinfatt, Tim, Rothaug, Moritz, Berr, Susanne, Hünig, Thomas, Beilhack, Andreas, Wajant, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399339/ https://www.ncbi.nlm.nih.gov/pubmed/30833543 http://dx.doi.org/10.1038/s41419-019-1456-x |
Ejemplares similares
-
CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism
por: Nelke, Johannes, et al.
Publicado: (2020) -
Editorial: TNFRSF agonists: mode of action and therapeutic opportunities
por: Obermajer, Nataša, et al.
Publicado: (2023) -
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity
por: Zaitseva, Olena, et al.
Publicado: (2023) -
A TNFR2-Specific TNF Fusion Protein With Improved In Vivo Activity
por: Vargas, Juan Gamboa, et al.
Publicado: (2022) -
CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
por: Medler, Juliane, et al.
Publicado: (2022)